Engine Biosciences Pte. Ltd., a Singapore and Silicon Valley-based company using machine learning, combinatorial genetics and other technologies to hasten the discovery of gene interactions and biological networks underlying disease, has raised $43 million in series A financing. Polaris Partners led the round, which the company said would help it expand its portfolio of precision oncology therapeutics, prepare for its first clinical programs, and scale its technology platform.
The Research to Accelerate Cures and Equity for Children Act is leading to deep changes in pediatric cancer research. Passed in 2017 and fully implemented in 2020, the RACE Act requires companies to investigate targeted drugs for adult cancers in pediatric cancers as well “when the molecular target of the drugs are substantially related to a pediatric cancer.”
Locust Walk Acquisition Corp. CEO and biotech veteran Chris Ehrlich said his firm sifted through more than 90 prospects before setting on a merger with Effector Therapeutics Inc., focused on selective translation regulation inhibitors (STRIs) in cancer.
RSS
